ZI-MA4-1

N/A

Report date: 2025/02/14 17:42:23

Base Information

Drug NameZI-MA4-1
Drug Alias NameZI-MA4-1
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy
Mechanisms of ActionMelanoma-associated antigen 4 modulatorsNatural killer cell replacements
TargetsMelanoma-associated antigen 4
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungOvarian NeoplasmsSarcoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesZelluna Immunotherapy AS
China Registration ClassN/A

Develop Information

Active CompaniesCatalent IncZelluna Immunotherapy AS
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell LungOvarian NeoplasmsSarcoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A